Press coverage about Amarin (NASDAQ:AMRN) has trended somewhat positive on Sunday, Accern Sentiment Analysis reports. Accern identifies negative and positive news coverage by analyzing more than 20 million news and blog sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Amarin earned a media sentiment score of 0.18 on Accern’s scale. Accern also assigned news headlines about the biopharmaceutical company an impact score of 47.097908247349 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the next few days.
These are some of the headlines that may have impacted Accern Sentiment Analysis’s analysis:
- Amarin Co. (AMRN) Given Average Rating of “Hold” by Brokerages (americanbankingnews.com)
- Fcm Investments Trimmed By $319424 Its Healthequity (HQY) Holding; Amarin PLC (AMRN) Sentiment Is 1.22 (mtastar.com)
- Edited Transcript of AMRN earnings conference call or presentation 27-Feb-18 12:30pm GMT (finance.yahoo.com)
- Signals from Technical Perspective – Amarin Corporation plc (NASDAQ: AMRN) (wallstreetnews24.com)
- Does Amarin Corporation Plc – American Depositary Share (NASDAQ:AMRN) Have Gas After Even More Sellers … (nmsuherald.com)
Several brokerages recently weighed in on AMRN. Cantor Fitzgerald set a $10.00 price objective on shares of Amarin and gave the stock a “buy” rating in a research note on Wednesday, December 6th. ValuEngine upgraded shares of Amarin from a “sell” rating to a “hold” rating in a report on Wednesday, December 20th. BidaskClub lowered shares of Amarin from a “hold” rating to a “sell” rating in a report on Wednesday, January 31st. HC Wainwright restated a “buy” rating on shares of Amarin in a report on Thursday, March 1st. Finally, Zacks Investment Research upgraded shares of Amarin from a “sell” rating to a “hold” rating in a report on Thursday, February 15th. Two research analysts have rated the stock with a sell rating, one has assigned a hold rating and three have given a buy rating to the company’s stock. The stock currently has an average rating of “Hold” and a consensus target price of $7.75.
Amarin (NASDAQ:AMRN) last released its earnings results on Tuesday, February 27th. The biopharmaceutical company reported ($0.08) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.05) by ($0.03). The company had revenue of $53.87 million for the quarter, compared to analyst estimates of $52.73 million. The firm’s revenue for the quarter was up 39.2% compared to the same quarter last year. During the same quarter last year, the firm posted ($0.10) EPS. research analysts expect that Amarin will post -0.33 earnings per share for the current year.
In other news, insider Steven B. Ketchum sold 135,205 shares of the company’s stock in a transaction dated Tuesday, January 23rd. The shares were sold at an average price of $4.41, for a total transaction of $596,254.05. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, insider Steven B. Ketchum sold 128,257 shares of the company’s stock in a transaction dated Tuesday, January 2nd. The shares were sold at an average price of $4.25, for a total transaction of $545,092.25. The disclosure for this sale can be found here. In the last 90 days, insiders sold 426,720 shares of company stock worth $1,814,296. 3.72% of the stock is owned by company insiders.
COPYRIGHT VIOLATION WARNING: This report was originally published by WKRB News and is the property of of WKRB News. If you are accessing this report on another website, it was copied illegally and republished in violation of U.S. and international copyright and trademark law. The original version of this report can be accessed at https://www.wkrb13.com/2018/04/01/amarin-amrn-receiving-somewhat-favorable-news-coverage-report-finds.html.
Amarin Corporation plc, a biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States. The company's lead product is Vascepa, a prescription-only omega-3 fatty acid capsule, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia.
Receive News & Ratings for Amarin Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amarin and related companies with MarketBeat.com's FREE daily email newsletter.